Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1058 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Bronchogenic"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Not yet recruiting Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer
Condition: Bronchial Cancer
Intervention: Device: With and without SDB
4 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
5 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
6 Not yet recruiting Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Durvalumab;   Other: Durvalumab plus SBRT
7 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
8 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
9 Recruiting Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
Condition: Malignant Pleural Effusion
Intervention: Drug: Bevacizumab
10 Not yet recruiting A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Conditions: Locally Advanced Squamous Non-Small Cell Lung Cancer;   Metastatic Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Necitumumab;   Drug: Gemcitabine;   Drug: Carboplatin
11 Not yet recruiting Anti PD-1 Neo-adjuvant Treatment for NSCLC
Conditions: Non Small Cell Lung Carcinoma;   Stage I;   Stage II
Interventions: Drug: Pembrolizumab 200 mg IV single dose;   Drug: Pembrolizumab 200 mg IV twice interval 21 days;   Drug: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d;   Drug: Pembrolizumab 100 mg I.V single dose;   Procedure: Surgical resection of tumor
12 Not yet recruiting 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
Condition: Non-small-cell Lung Cancer
Intervention: Radiation: 18F-FDG
13 Not yet recruiting A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Condition: Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Interventions: Drug: Durvalumab and Tremelimumab;   Drug: AZD1775 and carboplatin (CBPT)
14 Not yet recruiting Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Carcinoma;   Small Cell Lung Carcinoma
Interventions: Procedure: Bronchoscopy with Bronchoalveolar Lavage;   Other: Laboratory Biomarker Analysis
15 Not yet recruiting PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Conditions: Neuroendocrine Tumors;   Carcinoma, Small Cell Lung;   Carcinoma, Large Cell Lung;   Merkel Cell Carcinoma;   Pheochromocytoma;   Paraganglioma;   Thyroid Cancer, Medullary;   Neuroendocrine Carcinoma
Intervention: Drug: PEN-221
16 Not yet recruiting A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Conditions: Advanced Solid Tumors;   Non-Small Cell Lung Carcinoma (NSCLC);   Triple Negative Breast Cancer (TNBC);   Endometrial Cancer;   Anaplastic Thyroid Cancer
Interventions: Drug: FAZ053;   Drug: PDR001
17 Not yet recruiting Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
Condition: Small Cell Lung Cancer (SCLC)
Interventions: Biological: Pembrolizumab;   Drug: Cisplatin;   Drug: Carboplatin;   Drug: Etoposide;   Radiation: Radiation therapy
18 Recruiting TR(ACE) Assay Clinical Specimen Study
Conditions: Carcinoma, Non-Small-Cell Lung;   Breast Neoplasms
Intervention: Device: TR(ACE) Assay Testing
19 Recruiting Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program
Conditions: Non-small Cell Lung Cancer;   Nivolumab;   Long-term Adverse Effects
20 Not yet recruiting Gefitinib Long-term Survivor Study
Condition: EGFR Mutation Positive Advanced Non-small-cell Lung Cancer

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years